• 1
    Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg. 1993; 217: 375384.
  • 2
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 11821186.
  • 3
    Tanigawa N, Lu C, Mitsui T, Miura S. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology. 1997; 26: 12161223.
  • 4
    El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998; 27: 15541562.
  • 5
    Yamamoto A, Dhar DK, El-Assal ON, Igarashi M, Tabara H, Nagasue N. Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. J Hepatol. 1998; 29: 290299.
  • 6
    Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK. Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res. 2000; 60: 14421448.
  • 7
    Westphal JR, Hullenaar RV, Peek R, et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer. 2000; 86: 768776.
  • 8
    Hsu PI, Chow NH, Lai KH, et al. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res. 1997; 17: 28032809.
  • 9
    Poon RTP, Ng IOL, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001; 33: 227235.
  • 10
    O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88: 277285.
  • 11
    Yoon SS, Eto H, Lin CM, et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res. 1999; 59: 62516256.
  • 12
    Perletti G, Concari P, Giardini RJ, et al. Anti-tumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. 2000; 60: 17931796.
  • 13
    Yokoyama Y, Green JE, Sukhatme VP, Ramakrisnan S. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinomas in a transgenic mouse model. Cancer Res. 2000; 60: 43624365.
  • 14
    Ding I, Sun JZ, Fenton B, et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 2001; 61: 526531.
  • 15
    Schuppan D, Cramer T, Bauer M, Strefeld T, Hahn EG, Herbst H. Hepatocytes as a source of collagen type XVIII endostatin [letter]. Lancet. 1998; 352: 879880.
  • 16
    Musso O, Rehn M, Theret N, et al. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res. 2001; 61: 4549.
  • 17
    Feldman AL, Tamarkin L, Paciotti GF, et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res. 2000; 6: 46284634.
  • 18
    Rahman MA, Dhar DK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res. 2001; 7: 13251332.
  • 19
    Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000; 6: 40644068.
  • 20
    Ichida F. New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996; 6: 112119.
  • 21
    Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology. 1996; 43: 14051409.
  • 22
    Morelli D, Lazzerini D, Cazzaniga S, et al. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. Clin Cancer Res. 1998; 4: 12211225.
  • 23
    Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer. 1998; 34: 20412045.
  • 24
    Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001; 47: 617623.
  • 25
    Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol. 2000; 17: 149152.
  • 26
    Read TA, Sorensen DR, Mahesparan R, et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol. 2001; 19: 2934.
  • 27
    Nagasue N, Ono T, Yamanoi A, et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg. 2001; 88: 515522.
  • 28
    Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol. 2001; 19: 3539.
  • 29
    Strik HM, Schluesener HS, Seid K, Meyermann R, Deininger MH. Localization of endostatin in rat and human gliomas. Cancer. 2001; 91: 10131019.